Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Rhea-AI Summary
Rein Therapeutics (NASDAQ:RNTX) closed a $57.5 million underwritten public offering of common stock, including full exercise of the underwriters’ over-allotment option.
The company sold 57.5 million shares at $1.00, with no warrants, and expects proceeds to fund its Phase 2 LTI-03 IPF trial and operations into Q1 2028.
Positive
- Gross proceeds of $57.5 million from common stock offering
- Full exercise of 7.5 million-share over-allotment option
- Offering priced at $1.00 per share with no warrants issued
- Runway extended, funding operations into Q1 2028
- Phase 2 LTI-03 IPF trial expected funded through completion
Negative
- Equity financing implies share dilution for existing shareholders
- Gross proceeds subject to underwriting discounts and expenses
News Market Reaction – RNTX
In the May 18 session, RNTX declined 0.95%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.6% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Equity offering | Negative | -24.0% | Underwritten common stock offering priced at $1.00 for $50M gross proceeds. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior equity offering news led to a sharp negative move of -23.99%, consistent with dilution concerns pressuring shares.
Over recent months, Rein’s news flow has centered on financing and advancing its LTI‑03 IPF program. A prior underwritten offering priced on Apr 30, 2026 for $50 million at $1.00 per share triggered a -23.99% next‑day move, highlighting sensitivity to dilution. Today’s closing of the upsized $57.5 million offering continues that capital‑raising theme but confirms demand and funding through a Phase 2 program and operations into 2028.
Key Terms
underwritten public offering financial
over-allotment option financial
registration statement on Form S-1 regulatory
prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Offering oversubscribed through full exercise of underwriters’ option, supported by strong investor demand
- Total gross proceeds increased to
$57.5 million - Offering consisted solely of common stock
- Proceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028
AUSTIN, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten public offering of common stock, including the full exercise of the underwriters’ over-allotment option. The financing included new and existing healthcare-focused investors, including Adar1 Capital Management LLC, Ikarian Capital LLC, Bios Partners, Stonepine Capital Management, Cable Car Capital LP, and Second Line Capital.
In total, 57.5 million shares were sold at
The transaction included the full exercise of the underwriters’ option to purchase an additional 7.5 million shares of common stock to cover over-allotments.
No warrants or other derivative securities were issued to the investors in connection with the financing.
Brian Windsor, Ph.D., Chief Executive Officer of Rein Therapeutics, commented, “We are pleased to have successfully completed this offering, including the full exercise of the over-allotment option. We appreciate the support from both new and existing investors as we continue to advance our Phase 2 RENEW trial of LTI-03 in IPF. This financing strengthens our balance sheet and positions us to execute on our clinical and operational priorities.”
Rein intends to use the net proceeds from the offering to:
- Fully fund its ongoing Phase 2 clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) through completion;
- Support continued clinical development, manufacturing, and regulatory activities; and
- Fund working capital and general corporate purposes.
Based on its current operating plan, the Company believes the net proceeds from this offering, together with its existing cash and cash equivalents, will be sufficient to fund its operations into the first quarter of 2028.
Offering Details
The securities described above were offered and sold pursuant to a registration statement on Form S-1 (File No. 333-295390), including a prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”), which was declared effective by the SEC on April 30, 2026.
The offering was made only by means of a prospectus. A final prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus may be obtained from Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC, at 7 World Trade Center, 46th Floor, New York, NY 10007, Attention: Capital Markets Team, Email: capmarkets@konikcapitalpartners.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.
About Rein Therapeutics
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S. Rein’s second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements of Rein Therapeutics, Inc. (“Rein”, the “Company”, “we”, “our” or “us”) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to expectations for the Company’s LTI-03 and LTI-01 product candidates and the closing of the offering. We use words such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “would,” “can,” “could,” “should,” “continue,” and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: (i) the risk that the net proceeds of the offering may not be sufficient to fully fund the Company’s ongoing Phase 2 clinical trial of LTI-03 through completion or fund the Company’s operations into 2028, and (ii) those other risks disclosed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 26, 2026, and in subsequent filings that the Company makes with the SEC. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of this press release, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Rein Therapeutics Investor Relations & Media Contact:
Investor Relations
